CN110891973B - Ror1抗体 - Google Patents

Ror1抗体 Download PDF

Info

Publication number
CN110891973B
CN110891973B CN201880045361.4A CN201880045361A CN110891973B CN 110891973 B CN110891973 B CN 110891973B CN 201880045361 A CN201880045361 A CN 201880045361A CN 110891973 B CN110891973 B CN 110891973B
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
set forth
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880045361.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN110891973A (zh
Inventor
阿米特·纳什瓦尼
萨蒂恩·戈希尔
马可·德拉佩鲁塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of CN110891973A publication Critical patent/CN110891973A/zh
Application granted granted Critical
Publication of CN110891973B publication Critical patent/CN110891973B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880045361.4A 2017-07-05 2018-07-05 Ror1抗体 Active CN110891973B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1710835.8 2017-07-05
GBGB1710835.8A GB201710835D0 (en) 2017-07-05 2017-07-05 ROR1 Antibodies
PCT/GB2018/051914 WO2019008377A1 (en) 2017-07-05 2018-07-05 ANTIBODY ROR1

Publications (2)

Publication Number Publication Date
CN110891973A CN110891973A (zh) 2020-03-17
CN110891973B true CN110891973B (zh) 2023-06-27

Family

ID=59592560

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880045361.4A Active CN110891973B (zh) 2017-07-05 2018-07-05 Ror1抗体

Country Status (11)

Country Link
US (3) US11466083B2 (https=)
EP (1) EP3649152B1 (https=)
JP (1) JP7242573B2 (https=)
CN (1) CN110891973B (https=)
AU (1) AU2018297630B2 (https=)
CA (1) CA3068196A1 (https=)
DK (1) DK3649152T3 (https=)
ES (1) ES3048696T3 (https=)
GB (1) GB201710835D0 (https=)
MX (1) MX2019015348A (https=)
WO (1) WO2019008377A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
US20230416942A1 (en) * 2020-08-21 2023-12-28 Yale University Nanobody Compositions and Methods of Use of the Same
KR20230053602A (ko) * 2020-08-24 2023-04-21 에피맙 바이오테라퓨틱스 (에이치케이) 리미티드 항-ror1 항체 및 관련된 이중특이적 결합 단백질
TWI818308B (zh) * 2020-09-03 2023-10-11 大陸商和鉑醫藥（上海）有限責任公司 標靶ｒｏｒ１的抗體或其抗原結合片段及製備方法和應用
CA3199586A1 (en) * 2020-11-23 2022-05-27 Samantha J. Busfield Antigen-binding molecules and uses thereof
WO2022182562A1 (en) * 2021-02-23 2022-09-01 BioLegend, Inc. ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN S1 AGENTS AND COMPOSITIONS
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
US20240309116A1 (en) * 2021-07-23 2024-09-19 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against ror1 and uses thereof
CN113956359B (zh) * 2021-10-29 2022-09-16 叶鑫淼 一种抗体及其在抗肿瘤中的应用
CN118302448A (zh) * 2021-12-28 2024-07-05 江苏恒瑞医药股份有限公司 抗ror1抗体和抗ror1抗体药物偶联物及其医药用途
WO2024012434A1 (en) * 2022-07-11 2024-01-18 Hansoh Bio Llc Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN115724973B (zh) * 2022-09-26 2023-07-11 普健生物（武汉）科技有限公司 抗人ror1高亲和力兔单克隆抗体及其应用
CN118440200B (zh) * 2023-04-21 2025-05-16 星奕昂(上海)生物科技有限公司 靶向ror1的抗体及其应用
CN121666398A (zh) * 2023-08-31 2026-03-13 正大天晴药业集团股份有限公司 靶向受体酪氨酸激酶样孤儿受体1的抗体及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010124188A1 (en) * 2009-04-23 2010-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
WO2011054007A1 (en) * 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
CN103429618A (zh) * 2010-12-10 2013-12-04 凯塞若公司 抗ror1抗体及其用途
CN104662044A (zh) * 2012-08-24 2015-05-27 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
WO2016016344A1 (en) * 2014-07-29 2016-02-04 Cellectis Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
WO2016115559A1 (en) * 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2016187220A2 (en) * 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004030811D1 (de) 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
WO2007146957A2 (en) 2006-06-13 2007-12-21 Irm Llc Ror1 as a therapeutic target for lung cancer
EP2513146B1 (en) 2009-12-18 2017-05-03 Kancera AB Antibodies against ror1 capable of inducing cell death of cll
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
US9758586B2 (en) 2010-12-01 2017-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ROR1 antibodies
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
CA2881981A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
JP2017522893A (ja) 2014-07-31 2017-08-17 セレクティスＣｅｌｌｅｃｔｉｓ Ｒｏｒ１特異的多重鎖キメラ抗原受容体
RU2753512C2 (ru) 2014-09-08 2021-08-17 Нэшнл Кэнсер Сентер Антитело против злокачественной клетки, противораковое лекарственное средство и способ тестирования злокачественного новообразования
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
EP3204416A1 (en) 2014-10-09 2017-08-16 EngMab AG Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
EP3253754B1 (en) 2015-02-02 2021-03-31 Kancera AB 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
CN108137669B (zh) 2015-05-18 2023-02-17 优瑞科生物技术公司 抗ror1嵌合抗原受体
EA201891066A1 (ru) 2015-10-30 2018-10-31 ЭнБиИ-ТЕРАПЬЮТИКС АГ Антитела к ror1
SG11201806120WA (en) 2016-01-20 2018-08-30 Scripps Research Inst Ror1 antibody compositions and related methods
KR20180100238A (ko) 2016-01-22 2018-09-07 얀센 바이오테크 인코포레이티드 항-ror1 항체, ror1 × cd3 이중특이성 항체, 및 이를 사용하는 방법
TW201730212A (zh) 2016-02-17 2017-09-01 宏觀基因股份有限公司 Ｒｏｒ１－結合分子及其使用方法
WO2017156479A1 (en) 2016-03-11 2017-09-14 Bluebird Bio, Inc. Ror1 chimeric antigen receptors
CN109563092B (zh) 2016-07-11 2021-09-14 坎塞拉有限公司 可用作哺乳动物酪氨酸激酶ror1活性的抑制剂的2-苯基咪唑并[4,5-b]吡啶-7-胺衍生物
WO2018119314A1 (en) 2016-12-22 2018-06-28 Ardeagen Corporation Anti-ror1 antibody and conjugates thereof
MX2019013998A (es) 2017-05-23 2020-07-29 Dragonfly Therapeutics Inc Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2).
MX2019015057A (es) 2017-06-23 2020-08-03 Velosbio Inc Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1).
WO2019005636A2 (en) 2017-06-25 2019-01-03 Systimmune, Inc. ANTI-ROR1 ANTIBODIES AND METHODS OF PREPARATION AND USE
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710838D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
WO2019016381A1 (en) 2017-07-20 2019-01-24 Nbe-Therapeutics Ag MULTISPECIFIC ANTIBODY PRODUCT BINDING TO DIFFERENT ROR1 EPITOPES
EP3665193A1 (en) 2017-08-07 2020-06-17 NBE Therapeutics AG Anthracycline-based antibody drug conjugates having high in vivo tolerability
AU2018360031B2 (en) 2017-11-03 2025-08-21 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-ROR1 immunotherapy
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010124188A1 (en) * 2009-04-23 2010-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
WO2011054007A1 (en) * 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
CN103429618A (zh) * 2010-12-10 2013-12-04 凯塞若公司 抗ror1抗体及其用途
CN104662044A (zh) * 2012-08-24 2015-05-27 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
WO2016016344A1 (en) * 2014-07-29 2016-02-04 Cellectis Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
WO2016115559A1 (en) * 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2016187220A2 (en) * 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Novel Humanised ROR1 Chimeric Antigen Receptors for the Treatment of Haematological Malignancies;Satyen Harish Gohil等;《Blood》;20161202;第128卷(第22期);文章号3361 *

Also Published As

Publication number Publication date
US20230220073A1 (en) 2023-07-13
EP3649152B1 (en) 2025-10-08
AU2018297630B2 (en) 2025-03-06
WO2019008377A1 (en) 2019-01-10
CN110891973A (zh) 2020-03-17
JP7242573B2 (ja) 2023-03-20
ES3048696T3 (en) 2025-12-11
MX2019015348A (es) 2020-07-20
DK3649152T3 (da) 2025-11-10
AU2018297630A1 (en) 2020-01-16
US11466083B2 (en) 2022-10-11
CA3068196A1 (en) 2019-01-10
JP2020530272A (ja) 2020-10-22
GB201710835D0 (en) 2017-08-16
US20250066472A1 (en) 2025-02-27
US20200354448A1 (en) 2020-11-12
EP3649152A1 (en) 2020-05-13

Similar Documents

Publication Publication Date Title
CN110891973B (zh) Ror1抗体
CN110891972B (zh) 对ror1和cd3的双特异性抗体
AU2016335750B2 (en) IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
CN104955845B (zh) 间皮素抗体和引起有效的抗肿瘤活性的方法
CN113330036B (zh) 结合pd-l1和ox40的双特异性抗体
WO2023151693A1 (zh) 包含抗tigit抗体和抗pd-1-抗vegfa双特异性抗体的药物组合物及用途
CN112442123B (zh) 抗cd47的单克隆抗体及其用途
TW202043277A (zh) 新型雙特異性抗體分子以及同時結合ｐｄ－ｌ１和ｌａｇ－３的雙特異性抗體
EP4093762A1 (en) Epstein-barr virus monoclonal antibodies and uses thereof
AU2022413444A1 (en) Dual mhc-targeting t cell engager
AU2019301138B2 (en) Monoclonal antibody for the detection of the antiretroviral drug emtricitabine (FTC, 2',3'-dideoxy-5-fluoro-3'-thiacytidine)
HK40071055A (en) Bispecific antibodies to ror1 and cd3
HK40017928B (en) Bispecific antibodies to ror1 and cd3
HK40017928A (en) Bispecific antibodies to ror1 and cd3
CN111040033A (zh) 靶向肿瘤细胞的抗人角蛋白18的单克隆抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant